LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

31.85 0.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.85

Max

32.56

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+70.17% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	501M 2.1B
Vorige openingsprijs	31.54
Vorige sluitingsprijs	31.85

Nieuwssentiment

By Acuity

100%

330 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mrt 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Infosys Agrees to Acquire Stratus

25 mrt 2026, 23:58 UTC

Winsten

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mrt 2026, 23:58 UTC

Winsten

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mrt 2026, 23:41 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mrt 2026, 23:41 UTC

Winsten

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mrt 2026, 23:34 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Declines on Possible Technical Correction -- Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mrt 2026, 21:58 UTC

Marktinformatie

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mrt 2026, 21:37 UTC

Marktinformatie

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mrt 2026, 21:14 UTC

Acquisities, Fusies, Overnames

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mrt 2026, 21:13 UTC

Acquisities, Fusies, Overnames

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

25 mrt 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

25 mrt 2026, 20:33 UTC

Acquisities, Fusies, Overnames

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mrt 2026, 20:31 UTC

Winsten

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

70.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.91 USD 70.17%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.